Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients’ quality of life.
Materials and methods. We conducted a prospective study of consecutive patients who received oncologic treatment in our institution and presented with dermatologic side effects. The severity of skin toxicity was assessed using the DLQI score and patients were prospectively followed to evaluate response to therapy. Univariate analysis of factors influencing the impact of skin toxicity on patient QOL was conducted.
Results. 52 patients were enrolled in the study. Patients who developed grade 3 and 4 skin toxicity had a higher DLQI score, with a greater impact on quality of life, but with better clinical outcome at 3 months follow-up, based on RECIST. Patients with moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy than those with mild AE (16/33 vs. 3/19, p = 0.035). Interestingly, female patients had a significantly poorer quality of life than male patients as assessed by the DLQI score (7.28 ± 7 vs. 3.7 ± 3.6, p = 0.038).
Conclusion. Cutaneous side effects are often encountered in cancer patients and their severity can be a surrogate marker for a positive clinical tumor response to therapy.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. M.E. LACOUTURE. Importance of dermatological care for patients with cancer The Asco Post 2012 http://www.ascopost.com/issues/september-15-2012/importance-of-dermatologic-care-for-patients-with-cancer/ [accessed December 2017].
2. CHMIELOWSKI B. TERRITO M. Cutaneous Complications in: Manual of clinical oncology Wolters Kluwer Philadelphia 2017: 29.
3. GULATTE M. Symptom Management in: Clinical guide to antineoplastic therapy – a chemotherapy handbook Oncology Nursing Society Pittsburgh Pennsylvania 2014:13.
4. BOERS-DOETS C.B. How to measure the impact of dermatologic and mucosal adverse events on symptom burden and quality of life The Asco Post 2013 http://www.ascopost.com/issues/december-15-2013/how-to-measure-the-impact-of-dermatologicand-mucosal-adverse-events-on-symptom-burden-and-quality-of-life/?utm_source=TrendMD&utm_medium=cpc&utm_campaign=The_ASCO_Post_TrendMD_0 [accessed December 2017].
5. NATIONAL CANCER INSTITUTE – DIVISION OF CANCER TREATMENT AND DIAGNOSIS Cancer therapy evaluation programhttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm [accessed December 2017].
6. FINLAY AY KHAN GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994; 19(3):201-6.
7. DEPARTMENT OF DERMATOLOGY QUALITY OF LIFE QUESTIONNAIRES CARDIFF UNIVERSITY http://sites.cardiffac.uk/dermatology/quality-of-life/dermatology-quality-of-life-index-dlqi/. [accessed December 2017].
8. HOFHEINZ RD DEPLANQUE G KOMATSU Y KOBAYASHI Y OCVIRK J RACCA P et al. Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhbitors in patients with solid tumors The Oncologist. 2016; 21:1-9.
9. LACOUTURE ME. Skin conditions can have severe impact in cancer patients Oncology 2011 http://www.practiceupdate.com/content/skin-conditions-can-have-severe-impact-in-cancer-patients/13155/62?trendmd-shared=1 [accessed December 2017].
10. PEREZ-SOLER R CHACHOUA A HAMMOND LA ROWINSKY EK HUBERMAN M KARP D et al. Determinants of tumor response and survival with erlotinib in patients with non small cell lung cancer J Clin Oncol. 2004; 22(16):3238-47.
11. VAN CUTSEM E TEIPAR S VANBECKEVOORT D PEETERS M HUMBLET Y GELDERBLOM H et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study J Clin Oncol. 2012; 30(23):2861-8.
12. PINTO C DI FABIO F ROSATI G LOLLI IR RUGGERI EM CIUFFREDA L et al. Observational study on quality of life safety and effectiveness of first line cetuximab plus chemotherapy in KRAS wild type metastatic colorectal cancer patients: the Observ Er Study. Cancer Med. 2016; 5(11):3272-81.